Earnings Call Summary | Co-diagnostics(CODX.US) Q1 2024 Earnings Conference
Earnings Call Summary | Co-diagnostics(CODX.US) Q1 2024 Earnings Conference
The following is a summary of the Co-Diagnostics, Inc. (CODX) Q1 2024 Earnings Call Transcript:
以下是聯合診斷公司（CODX）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Co-Diagnostics Q1 2024 recorded a revenue of $0.5 million, a decrease from the previous year. However, gross profit increased to $0.2 million from $0.1 million year on year.
There was an increase in operating expenses to $10.5 million, due to investments in research and development. Consequently, the company reported a net loss of $9.3 million, a significant increase from $5.8 million the previous year.
Liquidity position was strong with $50 million in cash and marketable securities by the close of the quarter.
聯合診斷2024年第一季度收入爲50萬美元，比上年有所下降。但是，毛利潤從同比10萬美元增至20萬美元。
由於研發投資，運營支出增加到1,050萬美元。因此，該公司報告的淨虧損爲930萬美元，較去年的580萬美元大幅增加。
流動性狀況良好，截至本季度末，現金和有價證券爲5000萬美元。
Business Progress:
業務進展：
The company has made strides in commercializing the Co-Dx PCR platform, coming close to completing the 510(k) submission to the FDA for associated products.
It is ramping up manufacturing capacity, with a new facility opening in Salt Lake City and another expansion in India.
Several leadership changes were made including the appointment of a new president. Additionally, progress was noted on the development and clinical evaluations of various tests for illnesses including tuberculosis and respiratory infections.
Co-Diagnostics is keen to establish itself as a global leader in point-of-care molecular diagnostics, focusing on underserved populations.
該公司在Co-Dx PCR平台商業化方面取得了長足的進步，接近完成向美國食品藥品管理局提交的相關產品的510（k）份申請。
它正在提高製造能力，在鹽湖城開設了一座新工廠，並在印度進行了另一項擴建。
領導層發生了幾次變動，包括任命新總統。此外，結核病和呼吸道感染等各種疾病檢測的開發和臨床評估也取得了進展。
Co-Diagnostics渴望將自己打造成牀旁分子診斷領域的全球領導者，專注於服務不足的人群。
More details: Co-diagnostics IR
更多詳情： 紅外聯合診斷
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。